Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating omalizumab versus placebo for idiopathic anaphylaxis completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaphylaxis
• Angioedema
• Bronchospasm
• Hypotension

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Anaphylaxis, Hypotension | Phase 2 | Status: COMPLETED | Results posted: 2019-07-01